NovaBay Pharmaceuticals (NYSE:NBY) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of NovaBay Pharmaceuticals (NYSE:NBY) in a report released on Thursday. The firm issued a hold rating on the stock.

Separately, Ascendiant Capital Markets reduced their target price on NovaBay Pharmaceuticals from $8.00 to $0.85 and set a “buy” rating on the stock in a report on Monday, November 11th.

NovaBay Pharmaceuticals Trading Up 3.1 %

NYSE NBY opened at $0.67 on Thursday. The firm has a market capitalization of $3.28 million, a PE ratio of -0.01 and a beta of 0.67. The business’s 50-day moving average price is $0.63 and its two-hundred day moving average price is $0.61. NovaBay Pharmaceuticals has a 12 month low of $0.36 and a 12 month high of $9.08.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc, a biopharmaceutical company, develops and sells eyecare, skincare, and wound care products in the United States and internationally. It offers Avenova Spray, a solution for removing foreign materials, including microorganisms and debris from skin around the eye, such as the eyelid; and wound care products, which are used for cleansing and irrigation as part of surgical procedures, as well as treating certain wounds, burns, ulcers, and other injuries under the NeutroPhase and PhaseOne brands.